Frost & Sullivan Research Service   Published: 24 Mar 2003
U.S. Therapeutic Apheresis Markets
  SERVICE HOMEPAGE
REPORT OVERVIEW BENEFITS OF THIS SERVICE MARKET SECTORS
TECHNOLOGIES LIST OF FIGURES ANALYST PRESENTATION
TABLE OF CONTENTS ORDERING INFORMATION FURTHER INFORMATION
   Report Overview
 

Uptake of Photopheresis in New Indications to Drive Future Revenue Growth

A growing body of conclusive scientific evidence supporting the value of photopheresis for off-label indications such as graft-versus-host disease (GVHD) and solid organ transplant rejection is increasing its use in such indications. Encouraged by these diseases' positive response to photopheresis, physicians are increasingly referring patients for this treatment, which also helps hospitals secure reimbursement more easily. Over the long-term, photopheresis may find application in indications such as leukemia, non-Hodgkin's disease, HIV infection, and inflammatory bowel disease.

This Frost & Sullivan research is a detailed overview of the various therapeutic apheresis procedures and the indications they are being used in. This report provides demand analysis, revenue forecasts, and profiles of major market participants. It discusses key market and technology trends, market drivers, restraints, challenges and strategies, as well as future potential of therapeutic apheresis.

Vendors Must Devote Greater Resources to Developing the Market

Since therapeutic apheresis constitutes a small part of apheresis vendors' overall business, they hesitate to plow resources into developing this market, either by funding clinical studies in potentially new indications or by expanding their sales force to increase awareness among physicians. Vendors tend to rely on word-of-mouth to spread the potential of therapeutic apheresis in off-label indications among the medical community. Lack of clinical documentation is a major concern for prescribing physicians, who need good scientific evidence to pressure health insurers to cover this therapy in off-label indications and to encourage hospitals to continue offering this service.

The key to overcoming this challenge lies in optimizing the value of existing clinical data, generated by the medical community, on the clinical benefits of therapeutic apheresis in numerous diseases. "Vendors need to lead efforts to establish an organization that can collate and review available clinical data from all apheresis centers," says the analyst. In addition, dedicating more resources to the education of physicians may contribute greatly to the realization of new growth opportunities for vendors.

Revenue Growth Dependent on Vendors Developing New Applications

Revenue growth in the therapeutic apheresis market is also reliant on the identification of new indications. "Vendors should look beyond the existing restraints of the market and assume more responsibility in developing new applications for therapeutic apheresis," says the analyst. For a relatively small investment, vendors can sponsor studies in new diseases under the direction of opinion leaders in the field. These efforts may result in attractive growth opportunities in off-label indications and establish the particular vendor as a proactive and committed player in the market.

   Benefits of this Service
 

Complete Overview of the U.S. Therapeutic Apheresis Market

Information on the U.S. therapeutic apheresis markets is sketchy at best. Market participants admittedly do not have a good handle on the size of the market (in terms of revenues or number of procedures performed each year), or potential growth opportunities offered by this market. This report provides a detailed picture of the current U.S. therapeutic apheresis markets by disease class (neurology; hematology & oncology, rheumatology, and other disorders), and by type of therapeutic apheresis procedure (plasmapheresis, plateletpheresis, red cell apheresis, leukapheresis, extracorporeal immunoadsorption, photopheresis and lipidpheresis). It also highlights potential growth areas in each of these market segments.

Strategies to Overcome the Major Challenges Facing the Market

The U.S. therapeutic apheresis market is facing challenges that threaten the survival of many of its participants. These challenges include the need to increase physician awareness about the benefits of therapeutic apheresis, in order to grow patient referrals to apheresis centers, and the need to exploit the potential of therapeutic apheresis in new indications. This report addresses each of these challenges and offer strategies that may help market participants overcome these obstacles.

Provides Market Perspective from all Role Players

During the course of this research, role players from all sectors of the U.S. therapeutic apheresis market were interviewed. These include existing and prospective vendors, therapeutic apheresis service providers, including nursing staff, prescribing physicians, and other relevant organizations. The report therefore reflects the perspectives of all market participants and provides insight into the unique challenges faced by the various role players.

   Market Sectors
 

Expert Frost and Sullivan analysts thoroughly examine the following market sectors in this report.

  • Neurology Disorders: The market for therapeutic apheresis in neurology disorders is small with little opportunities for growth in new diseases. The major diseases benefiting from therapeutic apheresis, more specifically standard plasma exchange, are myasthenia gravis, Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. Potential new indications include Pediatric Autoimmune Neuropsychiatric disorders associated with Streptococcal infections and Sydenham's chorea, both relatively rare disorders with little revenue generation potential.
  • Hematology and Oncology Disorders: This market segment currently generates more than half of total market revenues. The use of standard plasma exchange in the treatment of Thrombotic Thrombocytopenia purpura, and red cell exchange in the treatment of sickle cell disease are the major markets for therapeutic apheresis, followed by photopheresis in the treatment of cutaneous T-cell lymphoma and leukapheresis in the treatment of leukemia. Although short-term growth opportunities are limited, long-term growth in this market may come from increased use of photopheresis in bone-marrow-related cancers, such as leukemia and non-Hodgkin's lymphoma.
  • Rheumatology Disorders: Almost 90 percent of revenues generated in this market comes from extracorporeal immunoadsorption in the treatment of severe, refractory rheumatoid arthritis. Growth opportunities in this market over the short-term are limited. The use of photopheresis in the treatment of autoimmune diseases, such as scleroderma, rheumatoid arthritis, and systemic lupus erythematosus, may generate new revenue over the long-term.
  • Other Disorders: The bulk of revenues in this market comes from photopheresis in off-label indications, such as graft-versus-host disease and solid organ transplant rejection, followed by lipidpheresis in the treatment of hypercholesterolemia. Future revenue growth will be stoked by increased uptake of photopheresis in these off-label indications. Over the long-term, photopheresis may become an established treatment option in diseases such as inflammatory bowel disease, hepatitis C, pemphigus vulgaris and mastocytosis.
   Technologies
 

The following technologies are covered in this report.

  • Therapeutic Plasmapheresis: Therapeutic plasmapheresis, also known as therapeutic plasma exchange if the procedure involves infusion of replacement fluids: Separation and removal of plasma from a patient's whole blood in order to remove a disease substance, such as abnormal proteins or auto-antibodies circulating in the plasma. The remaining blood components and, if required, replacement fluids such as an albumin/saline plasma substitute or plasma from a screened, healthy donor are returned to the patient. Therapeutic plasmapheresis has the broadest application of the various therapeutic apheresis procedures. It is used in the treatment of disorders ranging from hematological diseases such as thrombotic thrombocytopenic purpura and idiopathic thrombocytopenia purpura, and rheumatological disorders such as rheumatoid arthritis and systemic vasculitis, to neurological conditions like the Guillain-Barre syndrome and myasthenia gravis.
  • Extracorporeal Immunoadsorption: A form of therapeutic plasmapheresis, which utilizes a protein A column to selectively remove immunoglobulin G and circulating immune complexes from the patient's plasma. Protein A is isolated from Staphylococcus aureus and bonded to a silica matrix. Extracorporeal immunoadsorption is designed for the treatment of diseases associated with pathogenic levels of immunoglobulin G and circulating immune complexes such as idiopathic thrombocytopenic purpura, hemolytic uremic syndrome, red cell aplasia, and rheumatoid arthritis.
  • Therapeutic Red Blood Cell Apheresis: Also known as erythrocytapheresis or red cell exchange is the separation and removal of a patient's abnormal red blood cells and, if required, replacement with red blood cells from screened, healthy donors. Sickle cell disease is the most common application for therapeutic red blood cell exchange. It may also be considered as a last-resort, life-saving treatment option for malaria patients unresponsive to other therapies.
  • Therapeutic Leukapheresis: Separation and removal of circulating white blood cells (leukocytes) in patients with extremely elevated levels of leukocytes. It is frequently used in the treatment of symptomatic leukemia with leukocytosis.
  • Therapeutic Plateletpheresis: Separation and removal of platelets in patients with abnormally high platelet counts. Used in the emergency treatment of primary thrombocytosis or essential thrombocythemia for immediate reduction in the platelet count.
  • Therapeutic Lipidpheresis: Therapeutic lipidpheresis also known as LDL-apheresis is a type of plasmapheresis based on the selective removal of LDL cholesterol and other lipoproteins from the plasma of patients with severe refractory hypercholesterolemia. The most widely used LDL-apheresis system comprises immunoadsorption of LDL cholesterol onto a dextran sulfate-cellulose adsorbent. Another system utilizes heparin-induced extracorporeal LDL precipitation. Therapeutic lipidpheresis is more effective than standard plasmapheresis in removing LDL cholesterol from patients with hypercholesterolemia. Unlike plasmapheresis, it does not remove HDL or "good" cholesterol.
  • Photopheresis: Photopheresis also known as extracorporeal photochemotherapy is the removal and reinfusion of autologous blood after the white blood cell portion was collected, treated extracorporeally with a photosensitizing drug such as 8-methoxypsoralen (8-MOP) and irradiated with ultraviolet A light. Since 8-MOP is only activated when exposed to ultraviolet A light, it poses no damage to non-exposed cells. When reinfused into the patient's body, lymphocytes bound to photoactivated 8-MOP act like a vaccine to alert the immune system to destroy any similar T-cells circulating in the blood. Photopheresis is only approved for the treatment of refractory cutaneous T-cell lymphoma but its off-label use in the treatment of graft-versus-host disease and prevention of solid organ transplant rejection is growing. Scientific literature from around the world suggests that photopheresis might also be beneficial in T-cell mediated autoimmune diseases such as pemphigus, lupus erythematosus, multiple sclerosis, rheumatoid arthritis, and scleroderma.
  • Therapeutic Cytapheresis: An umbrella term to describe the removal of a cellular component in whole blood in order to reduce clinical symptoms. Therapeutic cytapheresis is often used as a temporary measure in conjunction with chemotherapy and/or radiation therapy. Therapeutic cytapheresis may involve: removal of defective red blood cells and its replacement with healthy red blood cells in patients with sickle cell disease, removal of white blood cells in leukemia patients with leukocytosis, removal of platelets in patients suffering from thrombocythemia or thrombocytosis, or removal of alloreactive, T-cell lymphocytes from donor bone marrow or peripheral blood stem cells prior to a transplant, in order to reduce the incidence of graft-versus-host disease.
   Analyst Presentation
 

Click here to view the analyst presentation:


  Table Of Contents
  1 | EXECUTIVE SUMMARY
   Executive Summary
      1. Executive Summary

  2 | TOTAL MARKET FOR THERAPEUTIC APHERESIS
   Overview
      1. Report Scope and Segmentation
      2. Introduction
      3. Indications for Therapeutic Apheresis
      4. Reimbursement-1
      5. Reimbursement-2
      6. Therapeutic Apheresis Medical Device Suppliers-1
      7. Therapeutic Apheresis Medical Device Suppliers-2
      8. Emerging Players
      9. Therapeutic Apheresis Service Providers

  Market Dynamics
      1. Drivers
      2. Restraints
      3. Challenges and Strategic Recommendations

  Forecasts and Trends
      1. Demand Analysis
      2. Pricing
      3. Revenue Forecasts
      4. Analysis
      5. Market and Technology Trends

  Competitive Analysis
      1. Competitive Structure
      2. Market Share Analysis

  Frost & Sullivan Market Engineering Awards
      1. Market Leadership Award
      2. Technology Leadership Award
      3. Entrepreneurial Company Award

  3 | CURRENT APPLICATIONS
   Neurology
      1. Overview
      2. Potential Market Opportunities
      3. Revenue Forecasts
      4. Analysis
      5. Market Share Analysis

  Hematology and Oncology
      1. Overview
      2. Potential Market Opportunities
      3. Revenue Forecasts
      4. Analysis
      5. Market Share Analysis

  Rheumatology
      1. Overview
      2. Potential Market Opportunities
      3. Revenue Forecasts
      4. Analysis
      5. Market Share Analysis

  Other
      1. Overview
      2. Potential Market Opportunities
      3. Revenue Forecasts
      4. Analysis
      5. Market Share Analysis

   List of Figures
 

Chapter 2

  • Therapeutic Apheresis Markets: Classification by Indication (U.S.), 2002
  • Therapeutic Apheresis Markets: Reimbursement for Neurology Disorders (U.S.), 2002
  • Therapeutic Apheresis Markets: Reimbursement for Hematology and Oncology Disorders (U.S.), 2002
  • Therapeutic Apheresis Markets: Reimbursement for Rheumatology Disorders (U.S.), 2002
  • Therapeutic Apheresis Markets: Reimbursement for Other Disorders (U.S.), 2002
  • Therapeutic Apheresis Markets: Indications Typically Not Reimbursed by Health Insurers (U.S.), 2002
  • Therapeutic Apheresis Markets: Market Drivers Ranked in Order of Impact (U.S.), 2003-2009
  • Therapeutic Apheresis Markets: Market Restraints Ranked in Order of Impact (U.S.), 2003-2009
  • Therapeutic Apheresis Markets: Impact of Top Industry Challenges (U.S.), 2003-2009
  • Therapeutic Apheresis Markets: Strategies Addressing Market Challenges (U.S.), 2003-2009
  • Therapeutic Apheresis Markets: Disease Incidence and Prevalence for Plasmapheresis (U.S.), 2002
  • Therapeutic Apheresis Markets: Disease Incidence and Prevalence for Other Therapeutic Apheresis Procedures (U.S.), 2002
  • Therapeutic Apheresis Markets: Market Breakdown by Disease and Number of Procedures (U.S.), 2002
  • Therapeutic Apheresis Markets: Projected Number of Therapeutic Apheresis Procedures in Neurology Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Projected Number of Procedures in Hematology and Oncology Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Projected Number of Procedures in Rheumatology Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Projected Number of Therapeutic Apheresis Procedures in Other Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Projected Procedure Numbers by Type (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Prices of Therapeutic Apheresis Devices and Disposables (U.S.), 2002
  • Therapeutic Apheresis Markets: Revenue Forecasts (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Revenue Forecasts by Disease Class (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Revenue Breakdown by Disease Class (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Revenue Forecasts by Type of Procedure (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Revenue Breakdown by Type of Procedure (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Competitive Structure (U.S.), 2002
  • Therapeutic Apheresis Markets: Market Share Analysis by Revenue (U.S.), 2002
  • Therapeutic Apheresis Markets: Market Share Analysis by Number of Procedures (U.S.), 2002


Chapter 3

  • Therapeutic Apheresis Markets: Neurology Market Breakdown by Disease and Number of Procedures (U.S.), 2002
  • Therapeutic Apheresis Markets: Potential New Applications in Neurology Disorders--Disease Incidence and Prevalence (U.S.), 2002
  • Therapeutic Apheresis Markets: Revenue Forecast in Neurology Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Market Share Analysis by Revenue in Neurology Disorders (U.S.), 2002
  • Therapeutic Apheresis Markets: Market Share Analysis by Number of Procedures in Neurology Disorders (U.S.), 2002
  • Therapeutic Apheresis Markets: Hematology and Oncology Market Breakdown by Disease and Number of Procedures (U.S.), 2002
  • Therapeutic Apheresis Markets: Potential New Applications for Therapeutic Apheresis in Hematology and Oncology Disorders--Disease Incidence and Prevalence (U.S.), 2002
  • Therapeutic Apheresis Markets: Revenue Forecasts for Hematology and Oncology Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Revenue Forecast by Type of Procedure for Hematology and Oncology Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Revenue Breakdown by Type of Procedure in Hematology and Oncology Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Market Share Analysis by Revenue in Hematology and Oncology Disorders (U.S.), 2002
  • Therapeutic Apheresis Markets: Market Share Analysis by Number of Procedures in Hematology and Oncology Disorders (U.S.), 2002
  • Therapeutic Apheresis Markets: Rheumatology Market Breakdown by Disease and Number of Procedures (U.S.), 2002
  • Therapeutic Apheresis Markets: Potential New Applications in Rheumatology Disorders--Disease Incidence and Prevalence (U.S.), 2002
  • Therapeutic Apheresis Markets: Revenue Forecasts of Rheumatology Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Revenue Forecast by Type of Procedure in Rheumatology Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Revenue Breakdown by Type of Procedure in Rheumatology Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Market Share Analysis by Revenue in Rheumatology Disorders (U.S.), 2002
  • Therapeutic Apheresis Markets: Market Share Analysis by Number of Procedures in Rheumatology Disorders (U.S.), 2002
  • Therapeutic Apheresis Markets: Market Breakdown by Disease and Number of Procedures in Other Disorders (U.S.) 2002
  • Therapeutic Apheresis Markets: Potential New Applications in Other Disorders--Disease Incidence and Prevalence (U.S.), 2002
  • Therapeutic Apheresis Markets: Revenue Forecast in Other Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Revenue Forecast by Type of Procedure in Other Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Revenue Breakdown by Type of Procedure in Other Disorders (U.S.), 2002-2009
  • Therapeutic Apheresis Markets: Market Share Analysis by Revenue in Other Disorders (U.S.), 2002
  • Therapeutic Apheresis Markets: Market Share Analysis by Number of Procedures in Other Disorders (U.S.), 2002
  More Information
Please print out this form, complete your details and fax it to Frost & Sullivan:
Latin & North America:
Frost & Sullivan
Sales Department
7550 West Interstate 10
Suite 400
San Antonio
Texas 78229-5616. USA
Fax: 888.690.3329
Asia Pacific:
Frost & Sullivan
Sales Department
100 Beach Road
#29-01/11, Shaw Tower
Singapore 189702
SINGAPORE
Fax: +65 68900988
EMEA:
Frost & Sullivan
Sales Department
Sullivan House
4 Grosvenor Gardens
London SW1W 0DH. UK
Fax: +44(0) 1865 389 515
SERVICE INQUIRY


I would like information on:
U.S. Therapeutic Apheresis Markets (A341-01-00-00-00)

YOUR DETAILS

Name Address
Title
Company
Telephone State/Province
Fax Zip/Postal Code
Email Country
Select the markets that interest you Tell us the services that interest you
Aerospace & Defense
Automotive & Transportation
Business & Financial Services
Career Research
Chemicals, Materials & Foods
Consumer Products
Education
Electronics and Security
Energy & Power Systems
Environment & Building Technologies
Healthcare
Industrial Automation
Information & Communication Tech.
Measurement & Instrumentation
Metals & Minerals
 
Growth Partnership Services
Growth Team Membership
Growth Strategy Dialogue
Growth Consulting
Growth Workshops
Events
Corporate Training & Development
Best Practices Research
Technical Research
Econometric Research
Market Engineering Research
Customer Research
Financial Benchmarking & Analysis
Stratecast: Telecoms Strategic Forecasting
Career Opportunities
Press Support Services
Comments: (For instance 'Please send me more information on...')

  Further Information

Enquiries from:
Africa:
Tel:+27 21 680 3260
Email: enquiries@frost.com

Enquiries from:
Asia Pacific:
Tel: +65 68900999
Email: apacfrost@frost.com
 
Enquiries from:
Europe:
Tel: +44 (0) 20 7343 8383
Email: enquiries@frost.com
Enquiries from:
Latin America:
Tel: +54 11 4777 1550
Email: myfrost.la@frost.com
 

Enquiries from:
Middle East and North Africa:
Tel: +971.4.4331.893
Email: meenquiries@frost.com

Enquiries from:
North America:
Tel:+1.877.GO.FROST (463.7678)
Email: enquiries@frost.com
 

Enquiries from:
South Asia:
Tel: +91 (0) 22 6160 6666
Email: safrost@frost.com




 
For a full list of our offices click here.
 
Conseq